

Serial No. 10/631,871

**REMARKS**

Claims 1-22 are pending herein.

Claims 1-5 and 7-21 are rejected.

Claim 6 has been allowed.

Claim 22 is objected to as being dependent upon a rejected base claim. Claim 22 has been amended to incorporate that base claim.

**Claims 1-5 and 7-21, 35 U.S.C. 103(a)**

Claims 1-5 and 7-21 have been rejected under 35 U.S.C. 103(a) as being unpatentable over Umemura et al. US 4,902,503 (Umemura) in view of Trogolo et al US 2003/0118664 (Trogolo) and McGlothlin et al. US 6,329,444 (McGlothlin). This rejection and its accompanying remarks are respectfully traversed.

The present invention is directed to medical articles that comprise an antimicrobial region, which antimicrobial region comprises release-modulating *dispersed microparticles* within a latex polymer. The release-modulating microparticles comprise an antimicrobial agent and are adapted to release the antimicrobial agent.

Umemura discloses two types of antimicrobial latex compositions. The first type contains a homogeneous blend of a natural rubber latex or a synthetic polymer latex and protein silver. That type utilizes a latex, e.g., natural rubber latex, and a silver protein complex, protein-silver, *dissolved* in the aqueous phase of the latexes. See the Abstract, column 2, line 60, column 4, lines 45-48, column 4, 54-57 and column 5, lines 54-56. Thus, it is clear from the disclosures referred to that the protein silver is *required* by Umemura to be water soluble.

The second type uses a homogeneous blend of a cationic natural or synthetic rubber and soluble silver compounds, e.g., silver nitrate, among others. See, e.g., Abstract and column 4, lines 49-53. As with the protein silver, the water-soluble silver compounds are *dissolved* in the aqueous phase. See, e.g., column 8, lines 41-42. Umemura lacks any teaching of "release-modulating *microparticles* disposed within a latex polymer," as claimed. To the contrary, it is essential that the antimicrobial compound be *dissolved* in the aqueous phase of the latex. This is a direct teaching away from the present invention. In re Baird, 16 F.3d 380, 29 U.S.P.Q. 2d 1550 (Fed. Cir. 1994); also see the cases cited in MPEP 2141.02 VI and the cases cited therein.

Serial No. 10/631,871

Trogolo teaches microcapsules comprising an antimicrobial agent, typically in the form of a particle or particles encapsulated within a hydrophilic polymer. See Summary of the Invention.

Trogolo teaches a method of preparing an antimicrobial resin by incorporating an antimicrobial microcapsule into a polymer matrix.

Trogolo, however, does not teach latex polymers as either the encapsulating polymers or the matrix polymers. Trogolo actually teaches away from such a process at paragraph [0081], where the advantages of thermal/melt processing are disclosed, which advantages may be considered unique to the process disclosed and essential to the enhanced antimicrobial functioning of the resulting articles. See, e.g., MPEP 2141.02 VI and the cases cited therein. Also see the authorities cited above with respect to Umemura.

The rejection relies on the combination of two references *each* of which teaches directly away from the present claims. The use of insoluble or encapsulated silver compounds in the process of Umemura would have rendered it essentially inoperable. Similarly, the use of a latex and soluble silver compounds in the process of Trogolo would have rendered that process inoperable.

Thus the combination of teachings is directly contrary to what one of ordinary skill would have done with any expectation of success. See MPEP 2143.02 and the cases cited therein. At the very least, the combination would have been unwarranted by the disclosure of the references. *In re Gordon*, 733 F.2d 900, 221 U.S.P.Q. 1125 (Fed. Cir. 1984), *Carl Schenk, A.G. v. Norton Corporation*, 713 F.2d 782, 218 U.S.P.Q. 698, 702 (Fed. Cir. 1983), *In re Ratti*, 270 F.2d 810, 123 U.S.P.Q. 349 (CCPA 1959), MPEP 2143.01, last paragraph. Consequently, the rejection could only have been based on undue hindsight reconstruction of the references. MPEP 2142, second paragraph, *Akzo N.V. v. U.S. International Trade Commission*, 808 F.2d 1241, 1480-81, 1 U.S.P.Q.2d, 1241, 1246 (Fed. Cir. 1986), *cert. denied*, 482 U.S. 909 (1987), *Loctite Corp. v. Ultraseal Ltd.*, 781 F.2d 861, 874, 228 U.S.P.Q. 90-99 (Fed. Cir. 1985)

McGlothlin has been relied on only as a teaching of equivalence between polymer solutions and latexes for dip molding various medical devices. There is no teaching in McGlothlin pertaining to antimicrobials, either soluble or as microparticles. Thus this reference adds nothing relevant to the combination of references discussed above.

Serial No. 10/631,871

JAN 29 2008

Reconsideration and withdrawal of the rejection under 35 U.S.C. 103 is respectfully requested.

**OBJECTION TO CLAIM 22**

Claim 22 is objected to as being dependent upon a rejected base claim. Claim 22 has been amended to incorporate that base claim, which is believed to render the outstanding objection moot.


**CONCLUSION**

Applicant submits that, in addition to claims 6 and 22, all of the claims are in condition for allowance, early notification of which is earnestly solicited. Should the Examiner be of the view that an interview would expedite consideration of this Amendment or of the application at large, request is made that the Examiner telephone the Applicant's attorney at (703) 433-0510 in order to resolve any outstanding issues.

**FEES**

If there are any fees due and owing in respect to this amendment, the Examiner is authorized to charge such fees to deposit account number 50-1047.

Respectfully submitted,



David B. Bonham

Registration No. 34,297

Attorney for Applicant  
Mayer & Williams PC  
251 North Avenue West, 2<sup>nd</sup> Floor  
Westfield, NJ 07090  
(908) 518-7700 Tel.  
(908) 518-7795 Fax

**CERTIFICATE OF FACSIMILE  
TRANSMISSION**

I hereby certify that this document, and any document referenced herein, has been transmitted via facsimile to the US Patent and Trademark Office at 571-273-8300 on

1/29/08**David B. Bonham, Reg. No. 34,297**

(Printed Name of Person Faxing Correspondence)



(Signature)